Key statistics
On Friday, Sandoz Group AG (D8Y:BRN) closed at 61.26, -3.97% below its 52-week high of 63.80, set on Jan 27, 2026.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | 61.34 |
|---|---|
| High | 61.66 |
| Low | 61.26 |
| Bid | 61.56 |
| Offer | 61.65 |
| Previous close | 60.96 |
| Average volume | 2.50k |
|---|---|
| Shares outstanding | 440.00m |
| Free float | 421.63m |
| P/E (TTM) | 152.21 |
| Market cap | 26.91bn CHF |
| EPS (TTM) | 0.4018 CHF |
| Annual div (ADY) | 0.600 CHF |
|---|---|
| Annual div yield (ADY) | 0.98% |
| Div ex-date | Apr 17 2025 |
| Div pay-date | Apr 23 2025 |
Data delayed at least 15 minutes, as of Feb 06 2026.
More ▼
Announcements
- Sandoz launches renewable energy partnership to cover nearly 90% of electricity demand for European operations
- Sandoz delivers strong H1 2025 results, with accelerated sales growth in the second quarter
- Sandoz signs non-binding term sheet with Evotec SE to acquire its Just-Evotec Biologics in-house development and manufacturing capabilities in Toulouse, France
- Sandoz further asserts leadership in biosimilars, breaking ground on new Slovenia facility to expand European biosimilar hub and global market reach
- Sandoz launches first and only interchangeable denosumab biosimilars in US, providing new affordable treatment options for over 10 million patients[1]
- Sandoz launches Pyzchiva® autoinjector, first commercially available in Europe for ustekinumab biosimilars
- Sandoz reports Q1 2025 net sales in line with company expectations; full-year guidance confirmed
- Sandoz enters global collaboration license agreement with Henlius to commercialize leading oncology therapy, ipilimumab, in multiple indications
- Shareholders approve all resolutions proposed by Board of Directors at Annual General Meeting of Sandoz Group AG
- [Corrected] Sandoz files antitrust litigation against Amgen regarding patient access to etanercept biosimilar in the US
More ▼
